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We studied the role of the target of rapamycin
complex 2 (mTORC2) during neutrophil chemotaxis,
a process that is mediated through the polarization
of actin and myosin filament networks. We show
that inhibition of mTORC2 activity, achieved via
knock down (KD) of Rictor, severely inhibits neutro-
phil polarization and directed migration induced by
chemoattractants, independently of Akt. Rictor KD
also abolishes the ability of chemoattractants to
induce cAMP production, a process mediated
through the activation of the adenylyl cyclase 9
(AC9). Cells with either reduced or higher AC9 levels
also exhibit specific and severe tail retraction defects
that are mediated through RhoA. We further show
that cAMP is excluded from extending pseudopods
and remains restricted to the cell body of migrating
neutrophils. We propose that the mTORC2-depen-
dent regulation of MyoII occurs through a cAMP/
RhoA-signaling axis, independently of actin reorga-
nization during neutrophil chemotaxis.
INTRODUCTION
Chemotaxis is a process by which cells orient themselves and
move up a chemical gradient. It is important in a variety of phys-
iological and pathological events, including nerve growth, angio-
genesis, wound healing, metastatic invasion, and leukocyte
trafficking. Neutrophil chemotaxis is induced by chemoattrac-
tants that signal through pertussis toxin-sensitive Gi-coupled
as well as G12/13-coupled receptors (Wang, 2009). Binding of
chemoattractants to their receptors triggers the dissociation of
the heterotrimeric G proteins into a and bg subunits. The bg
subunits act as the main transducers of chemotactic signals by
activating several downstream effectors, including Ras, PI3K,
and phospholipase C, which ultimately lead to cell polarization
and migration (Bagorda et al., 2006).
The target of rapamycin (TOR) is an evolutionarily conserved
serine/threonine kinase that integrates signals from growth
factors, nutrients, and stress to regulate multiple processes,
including mRNA translation, cell-cycle progression, autophagy,
and cell survival (Bhaskar and Hay, 2007). In mammals, mTOR
is the component of two distinct multiprotein complexes,DevelopmemTOR complex 1 (mTORC1) and 2 (mTORC2). mTORC1 is
sensitive to rapamycin and contains mTOR and three associated
proteins: raptor, PRAS40, andmLST8.mTORC1 controls protein
synthesis and cell growth by phosphorylating the translation
regulator eIF-4E-binding protein 1 (4E-BP1) and the protein
kinase AGC member S6 kinase 1 (S6K1) (Sengupta et al.,
2010). mTORC2 is insensitive to rapamycin and is composed
of mTOR, Rictor, mLST8, mSin1, and Protor1 and 2 (Cybulski
and Hall, 2009). mTORC2 modulates cell survival in response
to growth factors by phosphorylating Akt, serum/glucocorticoid
regulated kinase 1 (SGK1), and protein kinase Ca (PKCa).
mTORC2 has also been found to regulate actin cytoskeleton
organization and cell migration in NIH 3T3, LN-18, U373, Rh30,
and HeLa cells (Gulati et al., 2009; Jacinto et al., 2004; Liu
et al., 2006). However, the mechanism by which this takes place
has not been elucidated. In the social amoebae Dictyostelium
discoideum the role of TORC2 in chemotaxis has been exten-
sively studied. Cells lacking LST8, Rip3 (the mSin1 homolog),
or Pianissimo (the Rictor homolog) all exhibit cell polarity and
chemotaxis defects (Chen et al., 1997; Lee et al., 1999, 2005).
Interestingly, it was recently demonstrated that these events
are regulated by the TORC2-mediated, PI3K-independent
PKBR1 phosphorylation, which occurs specifically at the leading
edge of chemotaxing cells (Kamimura et al., 2008).
In Dictyostelium, TORC2 is also essential for the chemoattrac-
tant-mediated activation of the adenylyl cyclase (AC) ACA, which
converts ATP into cAMP (Chen et al., 1997; Lee et al., 1999,
2005). In this system, Gbg independently activates PI3K and
TORC2 (Comer et al., 2005; Lee et al., 2005), and both signals
are required for ACA activation (Chen et al., 1997). Although
PI3K acts through the pleckstrin homology (PH) domain-contain-
ing protein cytosolic regulator of adenylyl cyclase (CRAC)
(Comer et al., 2005; Insall et al., 1994), the TORC2-mediated
ACA activation is regulated through Akt and PKBR1, a homolog
of Akt (Cai et al., 2010; Charest et al., 2010). Once synthesized,
cAMP remains inside cells and regulates chemotaxis by inhibit-
ing lateral pseudopod formation in a PKA-dependent fashion
(Stepanovic et al., 2005). cAMP is also secreted and acts as
the main chemoattractant in Dictyostelium by binding to specific
G protein-coupled receptors (Garcia and Parent, 2008).
In neutrophils it is well established that the addition of chemoat-
tractants triggers a transient increase in intracellular cAMP levels
(Ali et al., 1998; Spisani et al., 1996; Suzuki et al., 1996).
However, a clear correlation between cAMP levels and chemo-
taxis remains to be established (Elferink and VanUffelen, 1996;
Harvath et al., 1991; Spisani et al., 1996). We have shown that
chemoattractants give rise to a robust and transient activationntal Cell 19, 845–857, December 14, 2010 ª2010 Elsevier Inc. 845
Figure 1. Rictor KD Inhibits Neutrophil
Chemotaxis
(A) Rictor and mTOR are expressed in human
blood neutrophils and PLB-985 cells. Cells were
lysed and subjected to western analyses using
antibodies specific for Rictor and mTOR.
(B) Rictor KD in PLB-985 cells. Cells were lysed
and subjected to western analyses using anti-
bodies specific for Rictor and mTOR. Results are
representative of three independent experiments.
Also see Figures S1A and S1B.
(C) Under-agarose chemotaxis assay of Rictor
shRNA cells. Central well contains 500 nM fMLP.
Quantification was performed as described in the
Experimental Procedures. Results represent the
average ± SD of three independent experiments.
*p < 0.01 compared to the fMLP-stimulated WT
group. Also see Figure S1C.
(D) EZ-TAXIScan chemotaxis toward fMLP of Ric-
tor KD cells. The images show paths of individual
cells migrating in a gradient of fMLP as circles
(from red to blue with increasing time) overlaid
onto the final frame. For clarity, only cells that
moved in ten consecutive frames are shown.
However, all cells were included for quantification
(see Figure S3E). Data are representative of six
independent experiments. Also see Movie S1.
(E) Chemotaxis of Rictor KD cells to a point source
of fMLP. Images depicting differentiated cells
migrating to a micropipette containing 1 mM
fMLP were captured every 10 s. The star repre-
sents the position of the tip of the micropipette.
Overlay of bright field and fluorescent images
representative of three independent experiments
are presented. Also see Movie S2.
(F) Rictor shRNA cells show uniform F-actin accu-
mulation after fMLP stimulation. Differentiated
cells were stimulated with a uniform concentration
of fMLP (1 mM) for 10 min and fixed. F-actin was
detected by rhodamine-phalloidin staining.
Results are representative of three independent
experiments. Also see Figure S1D.
(G) Rictor shRNA cells show normal F-actin poly-
merization after fMLP stimulation. Differentiated
cells were stimulated with a uniform concentration of fMLP (1 mM) and fixed at indicated time point. F-actin content was detected by rhodamine-phalloidin stain-
ing. Results represent the average ± SD of three independent experiments. Also see Figure S1E.
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mTORC2 Regulates Chemotaxisof AC in neutrophils that is sensitive to pertussis toxin treatment,
but not to inhibition of PI3K activity (Mahadeo et al., 2007). We
also established that ACs 3, 4, 7, and 9 are expressed in human
neutrophils and suggested that AC9 is the predominant func-
tional AC isoform in these cells (Mahadeo et al., 2007). However,
the molecular components linking Gi-coupled chemoattractant
receptors to ACs remain to be identified.
In this report we set out to elucidate the role ofmTORC2 during
neutrophil chemotaxis. We show that cells lacking mTORC2
activity exhibit strong chemotaxis defects and loss of cell
polarity. Remarkably, we establish that this phenotype is due
to a loss of polarized actin assembly and myosin II (MyoII) regu-
lation, the latter occurring in a cAMP- and RhoA-dependent
fashion. Together, these findings provide novel insight into the
fundamental role of cAMP in chemoattractant-mediated
processes and present mechanistic information on how
mTORC2 regulates cytoskeletal elements during migration.846 Developmental Cell 19, 845–857, December 14, 2010 ª2010 ElsRESULTS
Rictor Is Required for Neutrophil Chemotaxis
We first assessed if components of mTORC2 are present in
neutrophils and PLB-985 cells—a pluripotent hematopoietic
cell line that can be differentiated into neutrophil-like cells
(Tucker et al., 1987). We found that both mTOR and Rictor are
expressed in neutrophils and PLB-985 cells and that their
expression is dramatically enhanced upon differentiation of
PLB-985 cells into neutrophil-like cells (Figure 1A; data not
shown). We screened potential active small hairpin RNAs
(shRNAs) that specifically target the human Rictor mRNA and
used shRNAs 1 and 2 to create stable PLB-985 Rictor shRNA
cells that retained 20% ± 8% and 21% ± 7% Rictor protein
levels, compared to control nonspecific (NS) shRNA-expressing
cells (Figure 1B). We differentiated PLB-985 cells into neutrophil-
like cells by incubating them with 1.3% DMSO for 6 daysevier Inc.
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mTORC2 Regulates Chemotaxis(differentiated PLB-985 cells are referred as WT) and found that
Rictor knockdown (KD) does not alter the ability of PLB-985 cells
to be differentiated into neutrophil-like cells (see Figure S1A
available online). To determine the effect of Rictor KD on
mTORC2 function, we measured the ability of N-formylme-
thionyl-leucyl-phenylalanine (fMLP), a strong chemoattractant
secreted by bacteria (Marasco et al., 1984), to phosphorylate
Akt (Bagorda et al., 2006) in differentiated NS and Rictor shRNA
cells. Although fMLP induced a robust phosphorylation of Akt at
Ser473 in NS shRNA cells, a site known to be phosphorylated by
mTORC2 (Sarbassov et al., 2005), in Rictor shRNA cells P-Akt
Ser473 was dramatically inhibited (Figure S1B). Yet, fMLP still
induced a robust phosphorylation on Thr308 of Akt (a site known
to be phosphorylated by PDK1; Alessi et al., 1997) in both cell
lines (Figure S1B), showing that Ser473 phosphorylation is not
a major regulator of Ser308 phosphorylation in neutrophils as
reported by others (Frias et al., 2006; Guertin et al., 2006; Jacinto
et al., 2006; Shiota et al., 2006).
We compared the chemotactic ability of WT, NS shRNA, and
Rictor shRNA cells under various conditions. We first used the
under-agarose assay to assess the ability of large populations
of cells to respond to chemotactic cues. We observed that, in
contrast to WT and NS shRNA cells, Rictor shRNA cells do not
migrate out of the loading wells toward a well containing an
optimal amount of fMLP (Figure 1C; Figure S1C; similar results
were obtained with LTB4 [data not shown]). To gain further
insight into this, we examined the behavior of the various cells
using the TAXIScan chemotaxis chamber, where cells are
exposed to linear gradients of chemoattractants (Nitta et al.,
2007). Under these conditions, the Rictor shRNA cells again
exhibited dramatic chemotaxis defects. Although the NS shRNA
cells traversed the well efficiently, the Rictor shRNA cells essen-
tially remained in place (Figure 1D; Figure S3E and Movie S1).
Similar findings were obtained using the micropipette assay.
In these experiments we mixed WT with NS shRNA or Rictor
shRNA cells and exposed them to a micropipette containing
1 mM fMLP. Therefore, the behavior of the shRNA-expressing
cells, which were easily identified because they also expressed
GFP, was directly comparable to WT cells. The NS shRNA cells
rapidly polarized and migrated to the tip of the micropipette
much like the WT cells (Figure 1E; Movie S2). The Rictor shRNA
cells were also able to sense the presence of chemoattractants
because they quickly adhered to the plate (Movie S2). However,
in contrast to NS shRNA cells, they did not appear to effectively
polarize. Indeed, these cells showed a uniform F-actin accumu-
lation throughout their periphery upon fMLP addition (Figure 1F;
Figure S1D). Yet, the levels and kinetics of actin polymerization
were identical in NS and Rictor shRNA cells (Figure 1G), and
the uropod marker, CD43, also remained polarized in Rictor
KD cells (Figure S1E). Therefore, it appears that the defect in
polarity is not resulting from weaker signals to actin assembly
or to polar-cap formation defects, although Rictor KD cells do
not show distinct uropods.
Because both mTORC1 and mTORC2 have been shown to
regulate cell migration, we used rapamycin treatment to assess
the role of mTORC1 during neutrophil chemotaxis. Neutrophils
isolated from fresh human blood were treated with rapamycin
for 30 min or 24 hr. The specificity of these treatments on
mTORC1 and mTORC2 was determined by assessingDevelopmemTORC1-mediated p70S6K Thr389 phosphorylation as well
as mTORC2-mediated Akt Ser473 phosphorylation. As previ-
ously shown in HeLa and PC3 cells (Sarbassov et al., 2006),
whereas short-term rapamycin treatment gave rise to a specific
inhibition of p70S6K phosphorylation, long-term treatment
clearly inhibited both mTORC1 and mTORC2 (Figure S2A).
Using transwell assays, we measured both fMLP- and
GM-CSF-mediated chemotaxis. As previously shown (Gomez-
Cambronero, 2003), we found that short-term rapamycin treat-
ment strongly inhibited GM-CSF-mediated neutrophil chemo-
taxis (Figure S2B). Yet, the same treatment did not significantly
modify fMLP-mediated chemotaxis (Figure S2B). In contrast,
long-term rapamycin treatment of neutrophils, which did not
alter cell viability, dramatically blocked fMLP-induced
neutrophil chemotaxis (Figure S2B). Similar findings were
obtained using the TAXIScan assay (Figure 2A; Figure S2D
and Movie S3) as well as the micropipette assay (data not
shown). Together, these findings show that mTORC2 specifi-
cally regulates G protein-coupled receptor-mediated neutrophil
chemotaxis.
Rictor Regulates Chemotaxis and Chemoattractant-
Induced cAMP Accumulation in an Akt-Independent
and PKC-Dependent Fashion
Because Akt is one of the downstream effectors of mTORC2, we
assessed the role of Akt during neutrophil chemotaxis. We used
the Akt inhibitor VIII, a highly specific Akt inhibitor that maintains
Akt in its PH domain-in conformation and dramatically impairs
Akt activity (Calleja et al., 2009). We found that Akt inhibition
completely abolished the fMLP-induced Akt Ser473 and Akt
Thr308 phosphorylation in both primary blood neutrophils and
in differentiated PLB-985 cells (Figure S2C; data not shown).
Using the under-agarose assay, we found that Akt inhibition
markedly, but not completely, inhibited neutrophil and differenti-
ated PLB-985 chemotaxis (Figure 2B; data not shown).
However, no significant difference between untreated and
treated neutrophil or differentiated PLB-985 cells was measured
using the TAXIScan assay (Figure 2C; Figure S2D and Movie S3;
data not shown). Because Akt inhibition does not mimic the
strong chemotaxis defect of the Rictor shRNA cells, we conclude
that Akt does not mediate the mTORC2 effects on chemotaxis in
neutrophils. We envision that the effect of Akt inhibition on the
under-agarose migration underscores a specific role for Akt
during migration in restricted environments that could be partly
dependent on mTORC2.
Because mTORC2 has been reported to mediate its effects on
the actin cytoskeleton via PKC in yeast and mammalian cells
(Loewith et al., 2002; Sarbassov et al., 2004), we next studied
the role of PKC in neutrophil chemotaxis. Neutrophils isolated
from human blood were incubated with GO6976, a specific
conventional PKC (cPKC) inhibitor (Qatsha et al., 1993), and
processed for chemotaxis assays. Using the under-agarose
assay, we found that cPKC inhibition completely inhibited
chemotaxis to fMLP (Figure 2B). Remarkably, when chemotaxis
was assessed using the TAXIScan assay, we observed that
cPKC-inhibited neutrophils could migrate directionally, but in
contrast to untreated controls, the back of the inhibited cells
remained strongly attached to the surface and did not retract,
leading to cells with long, extended tails (Figure 2D; Movie S3).ntal Cell 19, 845–857, December 14, 2010 ª2010 Elsevier Inc. 847
Figure 2. Rictor Regulates Chemotaxis and
Chemoattractant-Induced cAMP Accumu-
lation in an Akt-Independent and PKC-
Dependent Fashion
(A) EZ-TAXIScan chemotaxis toward fMLP of
rapamycin-treated human blood neutrophils.
Neutrophils were treated with or without 100 nM
rapamycin for 30 min. Data are representative of
three independent experiments. See legend
Figure 1D for details. Paths for 24 hr treatment
are not shown because no significant movement
could be detected. Also see Figures S2A, S2B,
S2D, and Movie S3.
(B) Under-agarose chemotaxis assay of Akt or
cPKC-inhibited human blood neutrophils. Neutro-
phils were treated with or without 10 mM Akt inhib-
itor VIII or 10 mM cPKC inhibitor GO6976 for
30 min. Central well contains 500 nM fMLP. Quan-
tification was performed as described in
Experimental Procedures. Results represent the
average ± SD of three independent experiments.
#p < 0.05 compared to the vehicle fMLP group.
(C) EZ-TAXIScan chemotaxis toward fMLP of Akt-
inhibited human blood neutrophils. Neutrophils
were treated with or without 10 mM Akt inhibitor
VIII for 30 min. Data are representative of five inde-
pendent experiments. See legend Figure 1D for
details. Also see Figure S2D and Movie S3.
(D) EZ-TAXIScan chemotaxis toward fMLP of
cPKC-inhibited human blood neutrophils. Neutro-
phils were treated with or without 10 mM GO6976
for 30 min. Inset shows a higher magnification
image of the cells. Data are representative of five
independent experiments. See legend Figure 1D
for details. Also see Figure S2D and Movie S3.
(E) Rictor KD inhibits fMLP-induced cAMP
production. Differentiated cells were stimulated
with 1 mM fMLP for 30 s, and intracellular cAMP
levels were measured before and after chemoat-
tractant addition. The inset shows the time-course
measurement of intracellular cAMP levels. SEM
values are presented from six independent exper-
iments. *p < 0.01 compared to the fMLP-stimu-
lated NS shRNA group. Also see Figure S2E.
(F) cPKC but not Akt regulates fMLP-induced
cAMP production. Human blood neutrophils
were treated with 10 mMAkt inhibitor VIII or 10 mM cPKC inhibitor GO6976 for 30 min. Intracellular cAMP levels were measured before and after chemoattractant
addition. Results represent the average ± SD of three independent experiments. *p < 0.01 compared to the fMLP-stimulated vehicle group. Also see Figure S2F.
Developmental Cell
mTORC2 Regulates ChemotaxisWe conclude that whereas cPKC inhibition leads to strong
chemotaxis defects, cPKC does not completely mediate the
effects of mTORC2 on neutrophil chemotaxis.
Because TORC2 is essential for chemoattractant-mediated
ACA activation in Dictyostelium, we next studied the role of
mTORC2 in regulating chemoattractant-mediated cAMP
synthesis. Although WT, NS shRNA, and Rictor shRNA cells
exhibited similar basal cAMP levels, the fMLP- and LTB4-medi-
ated increases in cAMP levels were specifically absent in Rictor
shRNA cells (Figure 2E; Figure S2E; data not shown). Yet, Akt
inhibition did not alter fMLP- or LTB4-mediated cAMP accumu-
lations in primary blood neutrophils and differentiated PLB-985
cells (Figure 2F; Figure S2F), again establishing that Akt does
not mediate the mTORC2 effects on neutrophil function. On
the other hand, cPKC inhibition dramatically inhibited fMLP-
and LTB4-mediated cAMP production (Figure 2F; Figure S2F).848 Developmental Cell 19, 845–857, December 14, 2010 ª2010 ElsKD of AC9 Expression Inhibits Chemoattractant-
Induced cAMP Production and Chemotaxis
To gain insight into the importance of chemoattractant-induced
cAMP increases inmediating the effects of mTORC2, we studied
the role of cAMP during neutrophil chemotaxis. Because phar-
macological interventions aimed at inhibiting cAMP signaling
are often toxic and nonspecific, we set out to generate cells
that are specifically devoid of chemoattractant-mediated
cAMP increases. From our previous knowledge of ACs in neutro-
phils, we proposed that AC9 is the predominant isoform in these
cells (Mahadeo et al., 2007). Therefore, we generated cells with
reduced AC9 expression and assessed their ability to synthesize
cAMP in response to chemoattractant stimulation. We screened
potential active shRNAs that specifically target the human AC9
mRNA and identified two sequences, shRNAs 1 and 2, that
give rise to a dramatic decrease in AC9 mRNA levels (Figure 3A).evier Inc.
Figure 3. Chemoattractant-Induced cAMP Production Is Mediated by AC9 and Is Required for Neutrophil Chemotaxis
(A) KD of AC9 expression in PLB-985 cells. Total RNA from cells was extracted, and AC9mRNA levels weremeasured by real-time RT-PCR. Results represent the
average ± SD of three independent experiments. Also see Figure S3A.
(B) KD of AC9 expression inhibits chemoattractant-induced cAMP production. Intracellular cAMP levels were measured before and 30 s after a 1 mM fMLP stim-
ulation in differentiated cells. The inset shows the time-course measurement of intracellular cAMP levels. SEM values are presented from six independent exper-
iments. #p < 0.05 compared to the buffer NS shRNA group; *p < 0.01 compared to the fMLP-stimulated NS shRNA group. Also see Figures S3B and S3C.
(C) Under-agarose chemotaxis assay of AC9 shRNA(1) cells. Central well contains 500 nM fMLP. Quantification was performed as described in Experimental
Procedures. Results represent the average ± SD of four independent experiments. *p < 0.01 compared to the fMLP-stimulated NS shRNA group. Also see Fig-
ure S3D.
(D) EZ-TAXIScan chemotaxis toward fMLP of AC9 KD cells. Data are representative of six independent experiments. See legend Figure 1D for details. Also see
Figure S3E and Movie S1.
(E) Chemotaxis of AC9 shRNA(1) cells to a point source of fMLP. Images depicting differentiated cells migrating to a micropipette containing 1 mM fMLP. The star
represents the position of the tip of the micropipette. Overlay of bright field and fluorescent images representative of three independent experiments are pre-
sented. Also see Movie S4.
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mTORC2 Regulates ChemotaxisSimilar to Rictor KD, we found that AC9 KD did not alter the
ability of PLB-985 cells to be differentiated into neutrophil-like
cells (Figure S3A). We next measured intracellular cAMP levelsDevelopmein response to chemoattractant addition. We found that cells
expressing AC9 shRNA hadmuch lower intracellular cAMP basal
levels that were barely increased after fMLP or LTB4 additionntal Cell 19, 845–857, December 14, 2010 ª2010 Elsevier Inc. 849
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mTORC2 Regulates Chemotaxis(Figure 3B; Figures S3B and S3C). Together, these findings
establish that chemoattractant-mediated cAMP synthesis is
mediated through the activation of AC9 in neutrophils.
To assess the role of chemoattractant-mediated cAMP fluxes
during neutrophil chemotaxis, we compared the chemotactic
ability of WT, NS shRNA, and AC9 shRNA cells. We observed
that, in contrast to WT and NS shRNA cells, AC9 shRNA cells
did not migrate efficiently out of the loading wells toward a well
containing fMLP (Figure 3C; Figure S3D; similar results were
obtained with LTB4). TAXIScan analyses revealed that, like NS
shRNA cells, AC9 shRNA cells appear to be able to sense the
chemoattractant gradient because they properly oriented and
polarized. However, in contrast to NS shRNA cells and similarly
to cPKC-inhibited cells, the back of AC9 shRNA cells remained
strongly attached to the coverslip and did not effectively retract
(Figure 3D; Figure S3E and Movie S1). In accordance with this
the AC9 shRNA cells barely moved across half of the chemo-
tactic chamber by the end of the movie. This behavior was
readily observed when 0.01, 0.1, or 1 mM fMLP was used,
showing that the chemotactic defectwas not secondary to a che-
moattractant sensitivity issue (data not shown). The inability of
the AC9 shRNA cells to move when placed in a chemoattractant
gradient was also obvious using the micropipette assay. In
contrast to the Rictor shRNA cells, the AC9 shRNA cells were
able to polarize toward the tip of the micropipette, as evidenced
by the presence of active membrane ruffling in the direction of
the gradient. Yet, AC9 shRNA cells did not effectively migrate
and basically remained stationary (Figure 3E; Movie S4).Exogenous Expression of AC9 Inhibits
Chemoattractant-Induced cAMP Production
and Chemotaxis
To gain more insight into the role of AC9 during neutrophil
chemotaxis, we generated PLB-985 cells exogenously express-
ing AC9-Venus. As negative and positive controls, we con-
structed PLB-985 cells exogenously expressing Venus or AC3-
eGFP, which is also expressed in neutrophils (Mahadeo et al.,
2007) (Figures S4A and S4B). We first studied the cellular distri-
bution of AC3-eGFP and AC9-Venus in chemotaxing cells and
found that both enzymes remain uniformly distributed on the
plasma membrane in response to chemotactic signals (Fig-
ure 4A)—an observation that is confirmed by looking at a 3D
reconstruction from confocal z stacks of AC9-Venus cells (data
not shown). As anticipated, we measured significantly higher
basal intracellular cAMP levels in both AC3-eGFP and AC9-
Venus expressing cells compared to Venus and WT cells,
showing that both enzymes are overexpressed and functional
(Figure 4B). Interestingly, although we found that fMLP stimula-
tion resulted in a significant increase in cAMP levels in AC3-
eGFP cells, cAMP production remained flat in AC9-Venus cells
(Figure 4B). We reason that, similarly to Dictyostelium cells over-
expressing ACA (Pitt et al., 1992), in AC9-Venus cells, upstream
regulators are limited and cannot activate the greater number of
AC9-Venus molecules present. In contrast, in AC3-eGFP cells,
WT levels of endogenous AC9 are present, and chemotactic
signals are normally transduced. Indeed, when we silenced
AC9 expression in AC3-eGFP cells, fMLP-mediated cAMP accu-
mulation was lost (Figure 4C; Figure S4C). Furthermore, as ex-850 Developmental Cell 19, 845–857, December 14, 2010 ª2010 Elspected, these cells exhibited back retraction and chemotaxis
defects similar to AC9 KD cells (data not shown).
We next examined the chemotactic properties of AC9-Venus
cells. Using the under-agarose assay, we found that, like Venus
cells, AC3-eGFP cells are able to sense the chemoattractant
gradient and migrate efficiently toward fMLP or LTB4. In
contrast, most of the AC9-Venus cells stayed in the loading
well with only a few cells migrating out (Figure 4D; Figure S4D).
The chemotaxis defect of AC9-Venus cells was more carefully
examined using the micropipette assay. Although Venus and
AC3-eGFP cells displayed similar normal chemotactic behav-
iors, the AC9-Venus cells developed very long tails as they tried
tomigrate up the chemoattractant gradient (data not shown; Fig-
ure 4E; Movie S5). Therefore, similar to the KD of AC9 and cPKC
inhibition, AC9-Venus expression did not affect the ability of cells
to sense the chemoattractant gradient and polarize. Rather,
altering AC9 levels affects the ability of cells to retract their
back during chemotaxis. These behaviors were also readily
evident when we used interference reflection microscopy (IRM)
to quantify the overall adhesion pattern of both AC3-eGFP and
AC9-Venus cells in response to chemoattractant stimulation
(Figure 4F; Movie S6). We found that AC9-Venus cells extended
long footprints at their back following chemoattractant stimula-
tion when compared to either Venus or AC3-eGFP cells. We
conclude that both the exogenous expression and the KD of
AC9 in PLB-985 cells lead to the loss of chemoattractant-medi-
ated cAMP production and to significant chemotactic defects.
cAMP Is Excluded from Extending Pseudopods in
Randomly Migrating and Chemotaxing Neutrophils
The back and side retraction defects observed in both AC9
shRNA and AC9-Venus cells prompted us to study the cellular
distribution of cAMP in chemotaxing neutrophils. To this end
we used a previously characterized cAMP FRET sensor, which
harbors the PKA regulatory subunit cAMP binding domain (B
domain) flanked by eYFP and eCFP (Bagorda et al., 2009). At
low cAMP levels, the probe remains in a close state, and the
FRET response is maximal. However, in the presence of
cAMP, a conformational change occurs, and the FRET response
is lost. NS shRNA and AC9 shRNA cells stably expressing the
cAMP probe were differentiated, exposed to uniform fMLP stim-
ulus, and the FRET responses were measured. Cells expressed
a uniform cytoplasmic distribution of the probe and comparable
levels of the eCFP and eYFP signals (Figure S5A). Figure 5A
depicts images of the basal FRET signal observed in both cell
lines. As expected from our biochemical measurements (Fig-
ure 3B), AC9 shRNA cells show a significantly higher basal
FRET signal compared to NS shRNA cells (Figure 5B). Upon
the addition of a uniform fMLP stimulus, we measured a sharp
and robust decrease in FRET efficiency (corresponding to higher
cAMP levels) specifically in the cell body of NS cells—the FRET
efficiency at the front of cells did not change upon fMLP addition
and remained high throughout the time course of the experiment
(Figure 5C; Movie S7) (the FRET signal remained unchanged in
the cell body of cells treated with buffer as depicted in Fig-
ure S5B). Furthermore, no change in FRET efficiency was
observed in either AC9 shRNA cells or in NS shRNA cells ex-
pressing a mutated version of the probe lacking the ability to
bind cAMP (Bagorda et al., 2009) (Figure 5C). Together, theseevier Inc.
Figure 4. Exogenous Expression of AC9
Inhibits Chemoattractant-Induced cAMP
Production and Chemotaxis
(A) Fluorescent images depicting the subcellular
distribution of Venus, AC3-eGFP, or AC9-Venus
in differentiated and migrating cells.
(B) Overexpression of AC9 results in higher basal
cAMP levels and inhibits chemoattractant-
induced cAMP production. Differentiated cells
were stimulated with 1 mM fMLP for 30 s, and
intracellular cAMP levels were measured before
and after chemoattractant addition. SEM values
are presented from six independent experiments.
#p < 0.05 compared to the buffer Venus group;
*p < 0.01 compared to the fMLP-stimulated Venus
group.
(C) KD of AC9 inhibits chemoattractant-induced
cAMP production in AC3-eGFP over-expressing
cells. Differentiated cells were stimulated with
1 mM fMLP, and intracellular cAMP levels were
measured at indicated time point. Results repre-
sent the average ± SD from three independent
experiments. Also see Figure S4C.
(D) Under-agarose chemotaxis assay of AC9-
Venus and AC3-eGFP cells. Central well contains
500 nM fMLP. Quantification was performed as
described in Experimental Procedures. Results
represent the average ± SD from three indepen-
dent experiments. *p < 0.01 compared to the
fMLP-stimulated Venus group. Also see Fig-
ure S4D.
(E) AC9-Venus cells exhibit long tail during chemo-
taxis. Images depicting differentiated cells
migrating to a micropipette containing 1 mM
fMLP were captured every 10 s. The star repre-
sents the position of the tip of the micropipette.
Bright-field images representative of three inde-
pendent experiments are presented. See also
Movie S5.
(F) AC9-Venus cells have stronger tail attachment.
Differentiated cells were stimulated with 1 mM
fMLP, and IRM images were recorded every
10 s. Black arrowheads represent the location of
the tail from the phase images. Representative
images are presented. Also see Movie S6.
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mTORC2 Regulates Chemotaxisfindings show that the probe recognizes AC9-specific changes
in cAMP concentrations that occur specifically within the cell
body of stimulated cells.
To gain more insight into the dynamics nature of the cellular
pool of cAMP, we exposed NS shRNA cells expressing the
cAMP probe to a micropipette filled with fMLP and assessed
the FRET response in actively chemotaxing cells. We observed
a higher FRET signal exclusively at the extending pseudopods
that persisted as the cells migrated (Figure 5D; Movie S7). Yet,
as we found following uniform chemoattractant stimulation, we
measured a decrease in the FRET signal (corresponding to
increases in cAMP levels) in the cell body as the cells moved
toward the tip of themicropipette. Figure 5Epresents a represen-
tative graph of the average FRET intensity along the migration
axis of a cell at successive times as the cell is chemotaxing. It
shows the extent by which the FRET intensity peaks at the ex-
tending pseudopod ofmigrating cells in a region several microm-
eters wide. This establishes that cAMP levels are lowest at theDevelopmefront of cells, where extensive actin remodeling takes place. In
addition, whereas the FRET signal remained highest at the front
of cells and lowest in the cell body, we observed a dynamic
change in FRET levels at the back of chemotaxing cells, where
the signal intermittently went up and down during chemotaxis
(Figure 5E; Movie S7). Taken together, these findings show
that cAMP levels are regulated in a spatiotemporal fashion
during chemotaxis. Whereas wemeasure lower levels in extend-
ing pseudopods, the back of cells exhibit dynamic cAMP varia-
tions as cells migrate toward the micropipette.
AC9 Regulates RhoA Activity and Phosphorylated
MyoII Levels
Because MyoII activity regulates tail retraction/adhesion (Ridley
et al., 2003), we next assessed MyoII activity in AC9-Venus cells
by visualizing the cellular distribution of phosphorylated myosin
regulatory light chain (P-MLC) following chemoattractant stimu-
lation. As previously described, we found P-MLC predominantlyntal Cell 19, 845–857, December 14, 2010 ª2010 Elsevier Inc. 851
Figure 5. cAMP Is Excluded from Extending Pseudopods in Randomly Migrating and Chemotaxing Neutrophils
(A) Basal FRET efficiency images represented in pseudo-color for differentiated NS shRNA and AC9 shRNA. Also see Figure S5A. At low cAMP levels observed in
AC9 KD cells, the probe remains in a close state, and the FRET response is maximal. In the presence of cAMP, a conformational change occurs, and the FRET
response is lost.
(B) Average basal FRET efficiency in differentiated NS shRNA and AC9 shRNA cells. Results represent the average ± SEM from eight independent experiments.
*p < 0.01 compared to NS shRNA cells.
(C) Time course of FRET efficiency following a uniform stimulation with 1 mM fMLP in NS shRNA and AC9 shRNA cells expressing the WT FRET sensor and in NS
shRNA cells expressing a mutated FRET sensor (R96E). Results represent the average ± SEM. The left panel shows the area where the FRET efficiency was
measured. The right panel depicts FRET efficiency images at different time points for NS shRNA and AC9 shRNA cells expressing the WT FRET sensor. Also
see Figure S5B and Movie S7.
(D) Differentiated NS shRNA cells were exposed to a micropipette containing 1 mM fMLP. The position of the micropipette is indicated by the star. The pseudo-
color image was taken from a representative experiment and represents FRET efficiency. Also see Movie S7.
(E) Graph depicting FRET intensities as a function of the position along the long axis of the cell for three consecutive time points acquired at 15 s interval (depicted
in red, blue, and black lines). Each point is an average over a smoothing region 5.6 mm across the cell width and 2.1 mm along the long axis of the cell (dashed
square indicates the size of the sliding smoothing region). The top arrow indicates the direction of cell migration. The green line depicts the intensity of CFP fluo-
rescence across the cell.
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Figure 6. AC9 Regulates RhoA Activity and
Phosphorylated MyoII Levels
(A) AC9-Venus and AC9 KD cells exhibit higher
P-MLC staining. Differentiated cells were
uniformly stimulated with 1 mM fMLP for 15 min
and fixed. Representative dual images are pre-
sented.
(B) AC9-Venus, AC9 shRNA, and Rictor shRNA
cells show higher P-MLC levels. Differentiated
cells were plated on fibronectin-coated plates for
10 min and uniformly stimulated with 1 mM fMLP.
At specific time points, samples were subjected
to western analyses using an anti-P-MLC anti-
body. Quantification of three experiments is pre-
sented as the amount of P-MLC after fMLP stimu-
lation relative to that of unstimulated cells (mean ±
SD). The amount of P-MLC at each point was stan-
dardized by dividing its value with the value of total
MLC of the same time point. Also see Figure S6A.
*p < 0.01, and #p < 0.05 compared to either Venus
or NS shRNA cells.
(C) AC9-Venus, AC9 shRNA, and Rictor shRNA
cells show defects in RhoA-GTP activation.
Differentiated cells were treated as in (B). Quantifi-
cation of three experiments is presented as the
amount of RhoA-GTP after fMLP stimulation rela-
tive to that of WT unstimulated cells (mean ±
SD). The amount of RhoA-GTP at each point was
standardized by dividing its value with the value
of total RhoA of the same time point. Also see Fig-
ure S6C. *p < 0.01, and #p < 0.05 compared to
either Venus or NS shRNA cells.
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mTORC2 Regulates Chemotaxisenriched at the posterior cortex and back in polarized Venus and
AC3-eGFP cells (Figure 6A) (Wong et al., 2007). In contrast, in
AC9-Venus and AC9 KD cells, the distribution of P-MLC dramat-
ically extended to the front of cells, and the level of P-MLC was
much stronger than in Venus or AC3-eGFP cells (Figure 6A).
Similarly, Rictor shRNA cells, which are devoid of fMLP-medi-
ated increase in cAMP levels and exhibit strong polarity defects,
displayed a weakly polarized bright P-MLC staining at their
periphery compared to NS shRNA cells (Figure 6A). To provide
more quantitative data, P-MLC levels were assessed by western
analyses following a uniform stimulation with fMLP. As shown by
immunofluorescence, we found that cells that did not show an
increased production of cAMP following fMLP addition (AC9-
Venus, AC9 KD, and Rictor KD) also showed a dramatic and
consistent increase in the level of P-MLC (Figure 6B; Figure S6A).
Because Rho-associated kinase (ROCK) regulatesMLC phos-
phorylation (Amano et al., 1996; Kimura et al., 1996), we next
asked if ROCK inhibition could suppress the strong chemotaxis
phenotype of the AC9 shRNA cells. For these experiments we
mixed WT cells with AC9 shRNA cells, which are labeled with
GFP, subjected them to a micropipette containing fMLP, and al-
lowed the cells to migrate directionally. We added DMSO, which
had no effect, followed by 1 mM of the ROCK inhibitor Y-27632
(Uehata et al., 1997) (Figure S6B and Movie S8). This low
concentration of Y-27632 induced the formation of longer tails
on theWT cells but did not otherwise inhibit their directed migra-Developmetion. On the other hand, Y-27632 treatment suppressed the
migration defect of the AC9 shRNA cells and allowed them to
efficiently migrate toward the micropipette tip, much like WT
cells. We conclude that the migration defects associated with
alterations in AC9 activity is mediated by increased MyoII phos-
phorylation levels, which leads to problems in back retraction
and efficient migration.
Because the small GTP-binding protein RhoA regulates back
retraction by activating ROCK (Riento and Ridley, 2003), we
next measured RhoA activation. We found that for both WT
and Venus cells, fMLP exposure gave rise to a drop in RhoA
activity after 1 min, followed by an enhancement in activity at
the 5 min time point (Figure 6C; Figure S6C). Interestingly, these
findings do not match RhoA-GTP levels measured in suspended
cells, which typically show low basal activity followed by an
increase in RhoA activity (Shi et al., 2009; Xu et al., 2005). We
reason that this is related to the fact that we perform our assays
on cells that are plated on fibronectin-coated surfaces because
we wish to mimic signals that occur during migration. In contrast
to what we measured in WT and Venus cells, AC9 shRNA and
Rictor shRNA cells exhibited high constitutive RhoA activity
that was not increased after fMLP addition. Furthermore, AC9-
Venus cells showed a sustained RhoA activity as early as
1 min after stimulation (Figure 6C; Figure S6C). Interestingly,
these RhoA activity dynamics are inversely correlated with the
cAMP dynamics we measured in WT, AC9-Venus, AC9 shRNA,ntal Cell 19, 845–857, December 14, 2010 ª2010 Elsevier Inc. 853
Figure 7. Schematic Diagram Depicting
How Chemoattractant-Mediated Increases
in Intracellular cAMP Levels Regulate
Neutrophil Back Retraction
See text for details.
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mTORC2 Regulates Chemotaxisand Rictor shRNA cells. InWT cells a peak in cAMP levels occurs
early after fMLP addition when RhoA activity is low (Figure 3B). In
contrast, in AC9-Venus and AC9 or Rictor shRNA cells, where
fMLP-mediated increases in cAMP levels are modest (AC9-
Venus) (Figure 4B) or absent (AC9 shRNA [Figure 3B]; Rictor
shRNA [Figure 2E]), we observed more sustained RhoA activity.
These findings show that the loss of chemoattractant-mediated
cAMP accumulations in AC9-Venus, AC9 shRNA, and Rictor
shRNA cells leads to constitutive RhoA-GTP levels, giving rise
to high ROCK activity and P-MLC levels in these cells. Together,
these effects lead to enhanced back activity and inefficient
migration.
DISCUSSION
mTORC2 has been shown to be involved in regulating the actin
cytoskeleton in various systems (Cybulski and Hall, 2009).
Consistent with findings in Dictyostelium (Chen et al., 1997;
Lee et al., 2005), we now establish that mTORC2 is a key regu-
lator of neutrophil polarity and chemotaxis. We show that
mTORC2 profoundly regulates the ability of neutrophils to
polarize F-actin and P-MyoII and to migrate directionally as
well as to produce cAMP in response to chemoattractant stimu-
lation. Because we find that AC9 KD cells specifically exhibit P-
MyoII defects, we envision that mTORC2 mediates its effects on
cell polarity by regulating both the actin and MyoII filament
assembly independently. We provide evidence that mTORC2
mediates its effects on MyoII assembly through a cAMP- and
RhoA-dependent pathway. The mechanism by which mTORC2
regulates the actin cytoskeleton remains to be determined
(Cybulski and Hall, 2009). We do show that the defect in polarity
does not result from weaker signals to F-actin assembly. Rather,
Rictor seems to regulate where F-actin is enriched. As shown in
Dictyostelium (Lee et al., 2005), we do not envision that this is854 Developmental Cell 19, 845–857, December 14, 2010 ª2010 Elsd
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tion. In Dictyostelium the effect of
TORC2 on chemotaxis has been shown
to occur through PKBR1, a homolog of
Akt that is myristoylated and persistently
localized at the plasma membrane, inde-
pendently of PI3K (Kamimura et al.,
2008). We now show that Akt inhibition
does not alter neutrophil chemotaxis to
a micropipette or in the TAXIScan
chamber, confirming results obtained
with neutrophils isolated from Akt1/
mice (Di Lorenzo et al., 2009). Therefore,
it appears that mTORC2 mediates its
effect on the actin cytoskeleton indepen-
dently of Akt in neutrophils. Importantly,
our findings also confirm previous reports
showing that uropod formation is depen-ent on the RhoA/ROCK/MyoII pathway (Lee et al., 2004; Rossy
t al., 2009) because Rictor KD cells do not display uropods.
From our findings we propose that chemoattractant-mediated
TORC2-dependent, transient cAMP accumulations are
quired to control back contraction and relaxation phases that
ccur during chemotaxis through phosphorylation and
ephosphorylation cycles ofMyoII. We propose thatMyoII phos-
horylation/dephosphorylation phases are regulated by two
ntagonistic pathways that act downstream of chemoattractant
ceptor activation (Figure 7). The activating pathway has been
roposed to bemediated via coupling toG12/13,which activates
hoA through PDZ-RhoAGEF (Wong et al., 2007; Xu et al., 2003).
e now provide evidence that the inhibitory pathway is
ontrolled via coupling to Gi, through AC9, in an mTORC2-
ependent fashion. We envision that cAMP, through PKA activa-
on, provides antagonistic signals to the RhoA/MyoII signaling
athway by phosphorylating RhoA, as previously reported (Eller-
roek et al., 2003; Lang et al., 1996). The inhibitory effects of PKA
ay also be mediated through phosphorylation of MLCK, which
hibits its activity (Howe, 2004). In addition, PKA has also been
hown to negatively regulate at least two RhoAGEFs: RhoAGEF
fc (Meiri et al., 2009); and AKAP-Lbc (Diviani et al., 2006).
will be interesting to determine if either of these also impacts
hoA activity in neutrophils. Remarkably, although MyoII activity
stimulated by phosphorylation of MLC at Ser19, the stability of
yoII filaments has been shown to be more significantly regu-
ted by MLC dephosphorylation at Thr18 and Ser19 (Ikebe
t al., 1988), and the dephosphorylation step is required for rapid
lament assembly through rapid disassembly of preexisting
laments (Watanabe et al., 2007). We envision that as cells are
hemotaxing up chemoattractant gradients, they experience
creased receptor activation that triggers activating and inhibi-
ry signals leading to the cycling of MyoII phosphorylation and
ephosphorylation and optimal migration.
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mTORC2 Regulates ChemotaxisThe relationship between intracellular cAMP levels and neutro-
phil chemotaxis has been controversial, with studies reporting
either stimulatory or inhibitory effects (Elferink and VanUffelen,
1996; Harvath et al., 1991; Spisani et al., 1996). One reason for
such discrepancy is the use of pharmacological activators and
inhibitors of ACs, phosphodiesterases, or PKA,which can exhibit
nonspecific effects. In addition the robust unregulated activation
of these enzymes can lead to non-physiological effects. Indeed,
Jones and Sharief (2005) have argued that spatially restricted
PKA activity is at play during neutrophil chemotaxis. Our FRET
analyses show that chemoattractant-mediated cAMP fluxes
occur specifically in the cell body and back of neutrophils, where
cAMP is poised to regulate RhoA. Remarkably, we also establish
that cAMP is specifically excluded from extending pseudopods
of randomly moving and chemotaxing cells. Although the mech-
anism underlying this remains to be determined, we envision that
a spatially activated pool of phosphodiesterase is active in pseu-
dopods and maintains low cAMP levels. In any case the spatial
restriction of cAMP to the cell body of neutrophils provides
a pool where cAMP can specifically act on effectors that regulate
retraction and contraction at the sides and back of polarized
cells. Indeed, traction forces have been shown to occur largely
at the side and rear of migrating neutrophils (Smith et al.,
2007). We now suggest that the spatiotemporal cAMP changes
elicited by chemoattractants tightly regulate these forces by
acting on RhoA and MyoII phosphorylation.
The synthesis of intracellular cAMP is tightly regulated by ACs.
Mammalian genomes harbor nine distinct G protein-coupled
ACs (AC1–AC9), composed of two sets of six transmembrane
domains followed by conserved cytosolic catalytic loops (Suna-
hara and Taussig, 2002). Although all transmembrane ACs are
stimulated by Gas, only AC1, AC5, AC6, and AC8 are inhibited
by Gai. Interestingly, all four AC isoforms expressed in neutro-
phils (AC3, AC4, AC7, and AC9) are insensitive to Gai inhibition
(Hacker et al., 1998; Mahadeo et al., 2007; Sunahara and Taus-
sig, 2002). Combined with our previous findings (Mahadeo et al.,
2007), we now establish that chemoattractant-mediated cAMP
accumulations in neutrophils are dependent on AC9 through
Gi-coupled signals. Unlike Gs-coupled receptors, which activate
AC by the direct interaction of GTP-Gas with AC, we reason that
the released Gbg subunits fromGi-coupled receptors, in concert
with cytosolic components, activate AC. In Dictyostelium, che-
moattractant receptors activate ACA in a Gbg-dependent
fashion and require input from the PI3K-dependent CRAC and
TORC2 (Chen et al., 1997; Insall et al., 1994; Lee et al., 2005).
Although input from PI3K is not required for AC9 activation in
neutrophils (Mahadeo et al., 2007), we now establish that che-
moattractant-mediated cAMP accumulations are dependent
on mTORC2, therefore highlighting the strong evolutionary
conservation of signaling cascades between these two systems.
The mechanism by which mTORC2 activates AC9 remains to be
determined. We do show that the chemoattractant-mediated
activation of AC9 depends on cPKC, but not Akt. Because
cPKC has been proposed to be controlled by mTORC2 (Sarbas-
sov et al., 2004), we predict that mTORC2 regulates AC9 activity
through PKC. Because many of the components of the AC acti-
vation cascade are membrane bound, and TORC2 activity has
been found to be spatially activated at the leading edge of Dic-
tyostelium cells (Kamimura et al., 2008), we envision thatDevelopmemTORC2 translocates to the plasma membrane where it is
poised to activate cPKC and AC9 upon chemoattractant addi-
tion in neutrophils.
EXPERIMENTAL PROCEDURES
Additional information is found in the Supplemental Experimental Procedures.
Cell Lines
HEK293T cells (ATCC) and Phoenix cells (Orbigen Inc., San Diego, CA, USA)
weremaintained on 100mmplate in DMEMmedia containing 10% fetal bovine
serum, 25 mM HEPES, 100 U/ml penicillin, and 100 mg/ml streptomycin at
37C, 5% CO2. For virus packaging, 80% confluence of cells was used for
transient transfection with lipofectamine methods. PLB-985 cells were main-
tained in an undifferentiated state in RPMI 1640 media containing 10% fetal
bovine serum, 25 mM HEPES, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin at 37C, 5% CO2. Cells were differentiated at a density of 4.5 3 10
5
cells/ml for 6 days in 1.3% DMSO RPMI 1640 complete media, and the status
of differentiation was monitored by CD11b staining.
Construct and Transfection of PLB-985 Cells
A retroviral approach was used to create a stable population of PLB-985 cells
expressing Venus, AC3-eGFP, and AC9-Venus. See Supplemental Experi-
mental Procedures for more details.
Chemotaxis Assay
(1) Micropipette chemotaxis assay: Differentiated cells were plated on
chambered cover slides coated with 0.2% gelatin, and a chemotactic
gradient was generated using the Eppendorf microinjector with Fento-
tips (Eppendorf, Germany) loaded with 1mM fMLP.
(2) Under-agarose assay: Chemotaxis of a large population of cells was
observed with the under-agarose assay, as described previously
(Comer et al., 2005). Briefly, 5 3 105 differentiated cells were resus-
pended in 5 ml mHBSS and plated into the outer wells. The middle
well was filled with 500 nM fMLP or 500 nM LTB4 in mHBSS, and the
gradient was allowed to establish for 10 min before plating cells. After
the cells were allowed to chemotaxis for4 hr, the wells were carefully
overlayed with phosphate buffer and visualized on a Leica DM IL
stereoscope. Each assay was performed in triplicate, and the results
are representative of at least three independent experiments on
different days. Quantification was performed by comparing the pixel
intensity in a selected area outside the well where the cells were loaded
(see yellow boxes in Figure 1C) using ImageJ. The pixel intensity in the
buffer condition was normalized to 1.
(3) EZ-TAXIScan chemotaxis assay: The EZ-TAXIScan chamber (Effector
Cell Institute, Tokyo, Japan) was assembled as described by themanu-
facturer. Cell migration was recorded every 15 s for 30 min at 37C in
a humidified environmental chamber. Coverslips and chips used in
the chamber were coated with 1% BSA at RT for 1 hr. All glass cover-
slips were ultrasonicated and washed before use. Cell migration anal-
ysis was conducted with MATLAB software. Single cells were tracked
over time using an algorithm for finding multiple objects in images
(Crocker and Grier, 1996). The average image was subtracted to avoid
tracking dead cells or other stationary features. Cell tracks were subse-
quently used to compute chemotaxis index (CI) and speed for each
tracked cell in each time step, as well as the average CI and average
speed for an experiment. Each image shows a representative section
of the final frame in the experiment, plus the locations of all cells iden-
tified and tracked in the section in all frames. The color indicates time:
going from red to blue as time evolves.
RhoA-GTP Pull-Down Assay
The pull-down assay for RhoA-GTP was performed as described by Wojciak-
Stothard et al. (2007) on cells plated on fibronectin-coated 12-well tissue-cul-
ture plates following 1 mM fMLP addition. See Supplemental Experimental
Procedures for more details.ntal Cell 19, 845–857, December 14, 2010 ª2010 Elsevier Inc. 855
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mTORC2 Regulates ChemotaxisLive Cell FRET Imaging and Analysis
A series of time-lapse images were collected as previously described
(Bagorda et al., 2009). Briefly, to measure FRET, images were acquired for
each set of measurements: (1) YFP fluorescence (514 nm excitation, 530 nm
LP emission filter); (2) CFP fluorescence (458 nm excitation, 475–505 nm BP
emission filter); and (3) FRET (458 nm, 530 nm LP emission filter). In order to
obtain a corrected FRET image, we acquired reference images from CFP-
YFP expressing cells, which do not FRET, and processed them using the
pFRET software (CircuSoft Instrumentation LLC, Hockessin, DE, USA). The
FRET efficiency images were used to obtain an average of FRET efficiency
values, which were further normalized to the average of the images preceding
fMLP stimulation as a reference value set to 100%.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and eight movies and can be found with this article online at
doi:10.1016/j.devcel.2010.11.004.
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